Boothbay Fund Management Boosts Stake in Syndax Pharmaceuticals

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC has significantly increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. According to a recent SEC filing, the institutional investor boosted its position in Syndax by 103.3% in the third quarter, now owning 261,933 shares worth approximately $4 million.

Why it matters

Syndax Pharmaceuticals is a promising biotech company working on innovative cancer treatments, and increased investment from institutional investors like Boothbay Fund Management suggests growing confidence in the company's pipeline and future prospects. This news could signal positive momentum for Syndax as it continues advancing its clinical programs.

The details

Boothbay Fund Management's increased stake in Syndax Pharmaceuticals comes as the biotech company has been making progress with its lead investigational candidate, entinostat, a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. Syndax has also been expanding its research platform aimed at enhancing the effectiveness of existing cancer therapies and addressing high unmet medical needs.

• Boothbay Fund Management increased its position in Syndax Pharmaceuticals by 103.3% in the 3rd quarter of 2026.